Literature DB >> 29723057

Myocardial Infarction and Ischemic Stroke after Exacerbations of Chronic Obstructive Pulmonary Disease.

Kieran J Rothnie1,2, Olivia Connell1, Hana Müllerová3, Liam Smeeth2, Neil Pearce2, Ian Douglas2, Jennifer K Quint1,2.   

Abstract

RATIONALE: Previous studies have suggested that acute exacerbations of chronic obstructive pulmonary disease (COPD) may be associated with increased risk of myocardial infarction and ischemic stroke.
OBJECTIVES: We aimed to quantify the increased risks of myocardial infarction and ischemic stroke risk associated with both moderate and severe acute exacerbation, and to investigate factors that may modify these risks.
METHODS: We performed a self-controlled case series to investigate the rates of myocardial infarction and ischemic stroke after acute exacerbation compared with stable time, within individuals. The participants were 5,696 adults with COPD with a first myocardial infarction (n = 2,850) or ischemic stroke (n = 3,010) and at least one acute exacerbation from the UK Clinical Practice Research Datalink with linked Hospital Episodes Statistics data.
RESULTS: The risks of both myocardial infarction and ischemic stroke were increased in the 91 days after an acute exacerbation. The risks were greater after a severe exacerbation (incidence rate ratio [IRR], 2.58; 95% confidence interval [CI], 2.26-2.95 for myocardial infarction; and IRR, 1.97; 95% CI, 1.66-2.33 for ischemic stroke) than after a moderate exacerbation (IRR, 1.58; 95% CI, 1.46-1.71 for myocardial infarction; and IRR, 1.45; 95% CI, 1.33-1.57 for ischemic stroke). The relative risks of myocardial infarction and ischemic stroke associated with acute exacerbation were lower among those with more frequent exacerbations (IRR, 1.42; 95% CI, 1.24-1.62 vs. IRR, 1.69; 95% CI, 1.50-1.91 for myocardial infarction; and IRR, 1.30; 95% CI, 1.15-1.48 vs. IRR, 1.68; 95% CI, 1.50-1.89 for ischemic stroke). Higher GOLD stage was associated with a lower rate of myocardial infarction (IRR, 1.98; 95% CI, 1.61-2.05 vs. IRR, 1.69; 95% CI, 1.45-1.98) but not for ischemic stroke. Aspirin use at baseline was associated with a lower risk of ischemic stroke (IRR, 1.28; 95% CI, 1.10-1.50 vs. IRR, 1.63; 95% CI, 1.47-1.80) but not with myocardial infarction.
CONCLUSIONS: Acute exacerbations of COPD are associated with an increased risk of myocardial infarction and ischemic stroke within 28 days of their onset. Several patient characteristics were identified that are associated with these events.

Entities:  

Keywords:  cardiovascular disease; electronic health care records; epidemiology

Mesh:

Substances:

Year:  2018        PMID: 29723057      PMCID: PMC6322039          DOI: 10.1513/AnnalsATS.201710-815OC

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN: 2325-6621


  33 in total

Review 1.  Role of viruses in exacerbations of chronic obstructive pulmonary disease.

Authors:  Jadwiga A Wedzicha
Journal:  Proc Am Thorac Soc       Date:  2004

Review 2.  Bacteria in exacerbations of chronic obstructive pulmonary disease: phenomenon or epiphenomenon?

Authors:  Sanjay Sethi
Journal:  Proc Am Thorac Soc       Date:  2004

3.  Tutorial in biostatistics: the self-controlled case series method.

Authors:  Heather J Whitaker; C Paddy Farrington; Bart Spiessens; Patrick Musonda
Journal:  Stat Med       Date:  2006-05-30       Impact factor: 2.373

4.  Absolute temperature, temperature changes and stroke risk: a case-crossover study.

Authors:  C Kyobutungi; A Grau; G Stieglbauer; H Becher
Journal:  Eur J Epidemiol       Date:  2005       Impact factor: 8.082

5.  Increased risk of myocardial infarction and stroke following exacerbation of COPD.

Authors:  Gavin C Donaldson; John R Hurst; Christopher J Smith; Richard B Hubbard; Jadwiga A Wedzicha
Journal:  Chest       Date:  2009-12-18       Impact factor: 9.410

6.  Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels.

Authors:  J A Wedzicha; T A Seemungal; P K MacCallum; E A Paul; G C Donaldson; A Bhowmik; D J Jeffries; T W Meade
Journal:  Thromb Haemost       Date:  2000-08       Impact factor: 5.249

Review 7.  Mortality in COPD: Role of comorbidities.

Authors:  D D Sin; N R Anthonisen; J B Soriano; A G Agusti
Journal:  Eur Respir J       Date:  2006-12       Impact factor: 16.671

Review 8.  The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature.

Authors:  Don D Sin; LieLing Wu; S F Paul Man
Journal:  Chest       Date:  2005-06       Impact factor: 9.410

9.  Lung function and risk of fatal and non-fatal stroke. The Copenhagen City Heart Study.

Authors:  T Truelsen; E Prescott; P Lange; P Schnohr; G Boysen
Journal:  Int J Epidemiol       Date:  2001-02       Impact factor: 7.196

10.  Risk of myocardial infarction and stroke after acute infection or vaccination.

Authors:  Liam Smeeth; Sara L Thomas; Andrew J Hall; Richard Hubbard; Paddy Farrington; Patrick Vallance
Journal:  N Engl J Med       Date:  2004-12-16       Impact factor: 91.245

View more
  13 in total

1.  Effect of Aclidinium Bromide on Major Cardiovascular Events and Exacerbations in High-Risk Patients With Chronic Obstructive Pulmonary Disease: The ASCENT-COPD Randomized Clinical Trial.

Authors:  Robert A Wise; Kenneth R Chapman; Benjamin M Scirica; Deepak L Bhatt; Sami Z Daoud; Sofia Zetterstrand; Colin Reisner; Esther Garcia Gil
Journal:  JAMA       Date:  2019-05-07       Impact factor: 56.272

2.  Relationship between risk, cumulative burden of exacerbations and mortality in patients with COPD: modelling analysis using data from the ETHOS study.

Authors:  Kirsty Rhodes; Martin Jenkins; Enrico de Nigris; Magnus Aurivillius; Mario Ouwens
Journal:  BMC Med Res Methodol       Date:  2022-05-25       Impact factor: 4.612

3.  Comparisons of exacerbations and mortality among regular inhaled therapies for patients with stable chronic obstructive pulmonary disease: Systematic review and Bayesian network meta-analysis.

Authors:  Hyun Woo Lee; Jimyung Park; Junwoo Jo; Eun Jin Jang; Chang-Hoon Lee
Journal:  PLoS Med       Date:  2019-11-15       Impact factor: 11.069

4.  The Impact of Exacerbation History on the Safety and Efficacy of Aclidinium in Patients with Chronic Obstructive Pulmonary Disease and Increased Cardiovascular Risk: ASCENT-COPD Trial.

Authors:  Robert A Wise; Kenneth R Chapman; Benjamin M Scirica; Sami Z Daoud; Dan Lythgoe; Esther Garcia-Gil
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-03-18

5.  Virtual Reality Technology Combined with Comprehensive Pulmonary Rehabilitation on Patients with Stable Chronic Obstructive Pulmonary Disease.

Authors:  Xiangmei Xie; Jie Fan; Huihong Chen; Ling Zhu; Ting Wan; Jixin Zhou; Donghua Fan; Xiaoying Hu
Journal:  J Healthc Eng       Date:  2021-08-02       Impact factor: 2.682

Review 6.  COPD - do the right thing.

Authors:  Hanna Sandelowsky; Ulla Møller Weinreich; Bernt B Aarli; Josefin Sundh; Kristian Høines; Georgios Stratelis; Anders Løkke; Christer Janson; Christian Jensen; Kjell Larsson
Journal:  BMC Fam Pract       Date:  2021-12-11       Impact factor: 2.497

Review 7.  The Role of ABC Transporters in Lipid Metabolism and the Comorbid Course of Chronic Obstructive Pulmonary Disease and Atherosclerosis.

Authors:  Stanislav Kotlyarov; Anna Kotlyarova
Journal:  Int J Mol Sci       Date:  2021-06-23       Impact factor: 5.923

8.  Inhaled corticosteroids in COPD and the risk for coronary heart disease: a nationwide cohort study.

Authors:  Jiyoung Shin; Hee-Young Yoon; Yu Min Lee; Eunhee Ha; Jin Hwa Lee
Journal:  Sci Rep       Date:  2020-11-04       Impact factor: 4.379

9.  Accelerated FEV1 decline and risk of cardiovascular disease and mortality in a primary care population of COPD patients.

Authors:  Hannah R Whittaker; Chloe Bloom; Ann Morgan; Deborah Jarvis; Steven J Kiddle; Jennifer K Quint
Journal:  Eur Respir J       Date:  2021-03-04       Impact factor: 16.671

10.  Efficacy of Aclidinium Bromide According to Baseline Therapy: Post-Hoc Analysis of ASCENT-COPD Randomized Trial.

Authors:  Robert A Wise; Benjamin M Scirica; Deepak L Bhatt; Sami Z Daoud; Ferran Chuecos; Esther Garcia Gil; Kenneth R Chapman
Journal:  Adv Ther       Date:  2021-09-15       Impact factor: 3.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.